• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Therapy-related core binding factor acute myeloid leukemia.治疗相关的核心结合因子急性髓系白血病
Int J Hematol Oncol. 2023 Feb 14;12(1):IJH43. doi: 10.2217/ijh-2022-0004. eCollection 2023 Feb.
2
[Genetic abnormalities in core binding factor acute myeloid leukemia].[核心结合因子急性髓系白血病中的基因异常]
Rinsho Ketsueki. 2017;58(8):991-998. doi: 10.11406/rinketsu.58.991.
3
Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.核心结合因子原发性急性髓系白血病的分子与临床进展：恶性血液学转化研究的范例
Cancer Invest. 2000;18(8):768-80. doi: 10.3109/07357900009012209.
4
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.在患有t(8;21)(q22;q22)急性髓系白血病的成年患者中，CCND1和CCND2基因的突变是常见事件。
Leukemia. 2017 Jun;31(6):1278-1285. doi: 10.1038/leu.2016.332. Epub 2016 Nov 15.
5
Primary peritoneal myeloid sarcoma in association with fusion.伴有融合的原发性腹膜髓系肉瘤。
Leuk Res Rep. 2021 Mar 16;15:100238. doi: 10.1016/j.lrr.2021.100238. eCollection 2021.
6
Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.急性髓性白血病中由inv(16)(p13q22)和t(16;16)(p13;q22)编码的CBFβ/MYH11融合信息的异质性。
Blood. 1995 Jun 15;85(12):3695-703.
7
Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.成人急性髓系白血病中最常见染色体易位的临床意义
J Natl Cancer Inst Monogr. 2008(39):52-7. doi: 10.1093/jncimonographs/lgn003.
8
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.对一组初发急性髓系白血病成年患者进行前瞻性研究，比较t(8;21)和inv(16)的细胞遗传学和分子遗传学检测：癌症与白血病B组研究。
J Clin Oncol. 2001 May 1;19(9):2482-92. doi: 10.1200/JCO.2001.19.9.2482.
9
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.达沙替尼联合化疗用于初治核心结合因子急性髓系白血病：癌症和白血病B组研究10801
Blood Adv. 2020 Feb 25;4(4):696-705. doi: 10.1182/bloodadvances.2019000492.
10
Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?核心结合因子（CBF）急性髓系白血病：通过逆转录聚合酶链反应（RT-PCR）进行分子监测在临床上有用吗？
Eur J Haematol. 2003 Sep;71(3):143-54. doi: 10.1034/j.1600-0609.2003.00131.x.

引用本文的文献

1
Predicting :: genetic abnormalities in acute myeloid leukemia from bone marrow smears: Can artificial intelligence do better?预测：基于骨髓涂片诊断急性髓系白血病中的基因异常：人工智能能否做得更好？
iScience. 2025 Jun 25;28(7):112998. doi: 10.1016/j.isci.2025.112998. eCollection 2025 Jul 18.
2
Germline de novo alterations of RUNX1T1 in individuals with neurodevelopmental and congenital anomalies.患有神经发育和先天性异常个体中RUNX1T1的种系新生改变。
HGG Adv. 2025 Jan 9;6(1):100384. doi: 10.1016/j.xhgg.2024.100384. Epub 2024 Nov 20.

本文引用的文献

1
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.回顾性比较新诊断的核心结合因子（CBF）急性髓系白血病患者接受 Fludarabine、Cytarabine、GCSF（FLAG）联合 gemtuzumab ozogamicin（GO）或 Idarubicin（IDA）治疗的生存和反应：MD Anderson 经验 174 例患者。
Am J Hematol. 2022 Nov;97(11):1427-1434. doi: 10.1002/ajh.26700. Epub 2022 Sep 27.
2
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
4
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.自体造血干细胞移植治疗低危急性髓系白血病：单中心经验与当前挑战
Int J Hematol. 2022 Oct;116(4):586-593. doi: 10.1007/s12185-022-03370-4. Epub 2022 May 13.
5
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".核心结合因子急性髓系白血病：70例接受统一“7+3”方案治疗患者的长期预后
Blood Cancer J. 2022 Apr 7;12(4):55. doi: 10.1038/s41408-022-00654-0.
6
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.地西他滨作为核心结合因子急性髓系白血病维持治疗的疗效。
Am J Hematol. 2022 May;97(5):574-582. doi: 10.1002/ajh.26496. Epub 2022 Feb 22.
7
Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.完全缓解的成人核心结合因子急性髓系白血病患者异基因移植时可测量残留病的预后价值
Bone Marrow Transplant. 2021 Nov;56(11):2779-2787. doi: 10.1038/s41409-021-01409-4. Epub 2021 Jul 16.
8
Core binding factor acute myelogenous leukemia-2021 treatment algorithm.核心结合因子急性髓系白血病-2021 治疗算法。
Blood Cancer J. 2021 Jun 16;11(6):114. doi: 10.1038/s41408-021-00503-6.
9
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).伴有inv(16)与t(8;21)的核心结合因子急性髓系白血病中的继发性细胞遗传学异常
Blood Adv. 2021 May 25;5(10):2481-2489. doi: 10.1182/bloodadvances.2020003605.
10
Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet.异基因造血干细胞移植改善了 2017 年欧洲白血病网络中具有中危和不良遗传学风险的成人核心结合因子急性髓系白血病患者的生存。
Transplant Cell Ther. 2021 Feb;27(2):173.e1-173.e9. doi: 10.1016/j.jtct.2020.10.010. Epub 2020 Dec 11.

治疗相关的核心结合因子急性髓系白血病

Therapy-related core binding factor acute myeloid leukemia.

作者信息

George Binsah, Yohannan Binoy, Mohlere Virginia, Gonzalez Anneliese

机构信息

Department of Hematology/Oncology, McGovern Medical School, The University of Texas Health Sciences Center at Houston, 6410 Fannin, Suite 830 Houston, TX 77030, USA.

出版信息

Int J Hematol Oncol. 2023 Feb 14;12(1):IJH43. doi: 10.2217/ijh-2022-0004. eCollection 2023 Feb.

DOI:10.2217/ijh-2022-0004
PMID:36874378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9979104/
Abstract

Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with poor overall survival, but occasionally t-AML can involve favorable-risk cytogenetics, including core binding factor AML (CBF-AML), which shows a recurrent chromosomal rearrangement with t(8;21) (q22;22) and 'inv(16) (p13.1;q22)/t(16;16)(p13.1;q22)', leading to '' fusion genes, respectively. Therapy-related CBF-AML (t-CBF-AML) accounts for 5-15% of CBF-AML cases and tends to have better outcomes than t-AML with unfavorable cytogenetics. Although CBF-AML is sensitive to high-dose cytarabine, t-CBF-AML has worse overall survival than CBF- AML. The objective of this review is to discuss the available data on the pathogenesis, mutations, and therapeutic options in patients with t-CBF-AML.

摘要

治疗相关的急性髓系白血病（t-AML）通常源于骨髓暴露于细胞毒性化疗和/或放射治疗。t-AML通常与总体生存率低相关，但偶尔t-AML可涉及有利风险的细胞遗传学，包括核心结合因子AML（CBF-AML），其显示出与t(8;21)(q22;22)和“inv(16)(p13.1;q22)/t(16;16)(p13.1;q22)”的复发性染色体重排，分别导致“ ”融合基因。治疗相关的CBF-AML（t-CBF-AML）占CBF-AML病例的5-15%，并且与细胞遗传学不良的t-AML相比往往有更好的结果。虽然CBF-AML对高剂量阿糖胞苷敏感，但t-CBF-AML的总体生存率比CBF-AML更差。本综述的目的是讨论t-CBF-AML患者发病机制、突变和治疗选择的现有数据。